Patient enrolment concludes in Vasomune’s Phase IIa Pegevongitide trial
The trial enrolled patients with presumed or confirmed viral or bacterial pneumonia who needed additional oxygen support.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance